Physician profile
Mark Peterson
NPI 1740226430
$12,697.19
in general payments reported to CMS, 2019-2025
12 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,858 · 2020: $63.59 · 2021: $3,250 · 2022: $56.13 · 2023: $910 · 2024: $1,516 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,081 · Food and Beverage: $1,044 · Consulting Fee: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,081.43 |
| Food and Beverage | $1,044.31 |
| Consulting Fee | $343.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supreme Orthopedic Systems, LLC | $6,371.77 | 2019-2025 | |
| Arthrex, INC. | $4,565.24 | 2019-2021 | |
| Stryker Corporation | $691.02 | 2019-2025 | Mako, Pangea, Alphavent |
| Hikma Pharmaceuticals USA | $343.50 | 2024 | Combogesic IV |
| Smith+Nephew, INC. | $231.78 | 2019-2021 | |
| Horizon Therapeutics Plc | $124.98 | 2023 | Krystexxa |
| Sanara Medtech INC. | $120.81 | 2024 | Celleraterx |
| Depuy Synthes Sales INC. | $116.13 | 2021 | |
| Zimmer Biomet Holdings, INC. | $45.46 | 2019 | |
| Fidia Pharma USA INC. | $36.37 | 2019-2024 | Hymovis |
| Moximed, INC | $33.33 | 2025 | Misha Knee System, Small, Left |
| Genentech USA, INC. | $16.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.